BiotechTube
Self-screen

Self-screen

Amsterdam, Netherlands· Est.
self-screen.nl
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Self-screen is a private, commercial-stage diagnostics company based in Amsterdam, specializing in molecular tests for cervical cancer prevention. Its product portfolio includes the HPV-Risk Assay for primary screening and the PreCursor-M+ methylation test for triage of HPV-positive women, aiming to reduce overtreatment. The company's strategy leverages translational science to create best-in-class assays that support global screening programs, including those utilizing self-sampling. With its products on the market and a focus on epigenetic biomarkers, Self-screen is positioned in the growing molecular diagnostics segment for HPV-related cancers.

OncologyWomen's Health

Technology Platform

Molecular diagnostics platform utilizing PCR-based HPV DNA detection/genotyping and DNA methylation analysis of host cell genes (e.g., FAM19A4, mir124-2) for objective cancer screening and triage.

Opportunities

The global shift to primary HPV screening creates a massive need for accurate, molecular triage tests to manage HPV-positive women, a core strength of Self-screen.
The growing adoption of self-sampling for cervical screening further drives demand for objective tests like methylation analysis that do not require a clinician-collected sample.

Risk Factors

Intense competition from large, established diagnostics corporations with greater resources and market access poses a significant challenge.
Success is also dependent on slow-moving processes like inclusion in national clinical guidelines and securing favorable reimbursement, which can hinder rapid adoption.

Competitive Landscape

Self-screen competes in the cervical cancer diagnostics market against giants like Roche (cobas HPV test), Hologic (Aptima HPV assay), and Qiagen (Digene HC2). In the triage segment, it competes with these companies' reflex genotyping strategies as well as BD's dual-stain cytology. Its differentiation lies in its proprietary, clinically validated epigenetic (methylation) technology for risk stratification.

More companies in Diagnostics & Precision Medicine →More companies in Netherlands →